Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary …
Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard
treatment for patients undergoing percutaneous coronary intervention. The availability of …
treatment for patients undergoing percutaneous coronary intervention. The availability of …
Towards precision medicine
EA Ashley - Nature Reviews Genetics, 2016 - nature.com
There is great potential for genome sequencing to enhance patient care through improved
diagnostic sensitivity and more precise therapeutic targeting. To maximize this potential …
diagnostic sensitivity and more precise therapeutic targeting. To maximize this potential …
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart …
PT O'Gara, FG Kushner, DD Ascheim, DE Casey… - Journal of the American …, 2013 - jacc.org
1.1. Methodology and Evidence Review The recommendations listed in this document are,
whenever possible, evidence based. The current document constitutes a full revision and …
whenever possible, evidence based. The current document constitutes a full revision and …
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American …
SD Fihn, JM Gardin, J Abrams, K Berra… - Journal of the American …, 2012 - jacc.org
The recommendations listed in this document are, whenever possible, evidence based. An
extensive evidence review was conducted as the document was compiled through …
extensive evidence review was conducted as the document was compiled through …
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …
Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack
Y Wang, X Zhao, J Lin, H Li, SC Johnston, Y Lin, Y Pan… - Jama, 2016 - jamanetwork.com
Importance Data are limited regarding the association betweenCYP2C19genetic variants
and clinical outcomes of patients with minor stroke or transient ischemic attack treated with …
and clinical outcomes of patients with minor stroke or transient ischemic attack treated with …
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis
JL Mega, T Simon, JP Collet, JL Anderson, EM Antman… - Jama, 2010 - jamanetwork.com
Content Clopidogrel, one of the most commonly prescribed medications, is a prodrug
requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on …
requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on …
[HTML][HTML] Carbamazepine-induced toxic effects and HLA-B* 1502 screening in Taiwan
Background Carbamazepine, an anticonvulsant and a mood-stabilizing drug, is the main
cause of the Stevens–Johnson syndrome (SJS) and its related disease, toxic epidermal …
cause of the Stevens–Johnson syndrome (SJS) and its related disease, toxic epidermal …
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
LH Cavallari, CR Lee, AL Beitelshees… - JACC: Cardiovascular …, 2018 - jacc.org
Objectives: This multicenter pragmatic investigation assessed outcomes following clinical
implementation of CYP2C19 genotype–guided antiplatelet therapy after percutaneous …
implementation of CYP2C19 genotype–guided antiplatelet therapy after percutaneous …
Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines
The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics
of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa …
of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa …